Shankus Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 31-10-2024
- Paid Up Capital ₹ 1.00 M
as on 31-10-2024
- Company Age 3 Year, 28 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 43.45 Cr
as on 31-10-2024
- Revenue 252.98%
(FY 2023)
- Profit 126.98%
(FY 2023)
- Ebitda 96.62%
(FY 2023)
- Net Worth 149.01%
(FY 2023)
- Total Assets 12.17%
(FY 2023)
About Shankus Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹43.45 Cr.
Dilip Chaudhary and Jagdish Chaudhary serve as directors at the Company.
- CIN/LLPIN
U24299GJ2021PTC127481
- Company No.
127481
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Nov 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Mahesana, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Shankus Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dilip Chaudhary  | Director | 23-Nov-2021 | Current |
| Jagdish Chaudhary | Director | 23-Nov-2021 | Current |
Financial Performance of Shankus Pharma.
Shankus Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 252.98% increase. The company also saw a substantial improvement in profitability, with a 126.98% increase in profit. The company's net worth Soared by an impressive increase of 149.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shankus Pharma?
In 2023, Shankus Pharma had a promoter holding of 100.00%. The company had 1 Subsidiary and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Keshav Holiday Resort Pvt LtdActive 32 years 7 monthsDilip Chaudhary and Jagdish Chaudhary are mutual person
- Neovant Therapeutics Private LimitedActive 1 year 9 months
Dilip Chaudhary and Jagdish Chaudhary are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 26 Dec 2023 | ₹1.95 Cr | Open |
Hdfc Bank Limited Creation Date: 04 Dec 2023 | ₹15.00 Cr | Open |
State Bank Of India Creation Date: 30 Aug 2022 | ₹15.91 Cr | Open |
How Many Employees Work at Shankus Pharma?
Shankus Pharma has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shankus Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shankus Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
